THE-IKEA-FOUNDATION
Shifting to alternative and plant-based proteins, supporting the market for electric 2&3 wheelers and providing targeted financial support for a fair and inclusive energy transition are among the highest impact opportunities global philanthropy can seize upon in the fight to reduce greenhouse gas (GHG) emissions, according to research commissioned by the IKEA Foundation.
The analysis, unveiled during the 2022 United Nations Climate Change Conference (COP27), was conducted in collaboration with the system change company, Systemiq and RMI, founded as the Rocky Mountain Institute, a nonprofit organisation working to accelerate the clean energy transition.
In 2021, the IKEA Foundation announced an additional €1 billion in funding for climate change programmes over a five-year period, with the strategic goal of quickly and significantly reducing global emissions. Of this commitment, €400 million has been earmarked for the Global Energy Alliance for People and Planet launched at COP26. The research conducted with Systemiqand RMI will inform how the IKEA Foundation deploys the remaining €600 million in climate funding.
The IKEA Foundation hopes publication of the research will drive greater investment in climate action efforts by the global philanthropic community, helping to keep alive the goal of limiting global warming to 1.5°C. Analysis by the ClimateWorks Foundationpublished in the run up to COP27 found that, despite a recent increase in climate philanthropy funding, still less than 2% of global philanthropic annual grants were dedicated to climate change mitigation in 2021.
Per Heggenes, CEO, IKEA Foundation, said: “We know that a rapid and sustained decrease in global emissions is required if the world is to meet its pledge of keeping global warming at or below 1.5°C. By sharing our research we hope to support and inspire other philanthropies, during this decisive decade for our planet, to step up their ambition to safeguard our environment.”
Jeremy Oppenheim, Founder of Systemiq, said: “Less than 2% of philanthropic capital goes to climate mitigation. This allocation needs to be scaled fast. But this is not just a volume game. It matters where and how philanthropy uses its capital. The methodology we developed with the IKEA Foundation and RMI could be the critical unlock that helps foundations prioritise the highest impact interventions to reduce emissions and deploy capital fast. The fact that the IKEA Foundation has chosen to open-source this analysis demonstrates their deep commitment to urgent climate action and belief in the catalytic role of a strategically coordinated philanthropic sector. “
Lena Hansen, Interim Chief Program & Strategy Officer, RMI said: “Collaboration is critical to implement solutions that set off catalytic tipping points and keep warming to 1.5C. RMI commends the IKEA Foundation for sharing this research with the world, and we hope that it helps spark radical collaboration to accelerate solutions to the climate crisis.”
The research considered five systems in which the consumption and production of GHG emissions needs to be transformed to limit global warming to 1.5°C: Energy & Power, Food & Land Use, Industry, Transport, and Buildings. It identified the key levers of change and high impact opportunity areas within these systems by considering: their potential to significantly reduce GHG emissions by 2030; the near-term viability of the technology required to meet the potential; their cost-effectiveness; and the ‘value add’ global philanthropy could provide in encouraging and maximising impact.
Some of the high impact opportunities identified are:
- Providing targeted financial support to a fair and inclusive energy transition
- Creating a market for minimizing upstream methane emissions
- Creating the capacity for peatland protection/ restoration projects at government level
- Stimulating a shift to alternative and plant-based protein
- Creating the market & enabling environment for reducing methane emissions in agriculture
- Invigorating efforts to strengthen value chains which can reduce losses
- Supporting the market for electric 2 & 3 wheelers through operations and financing innovation
- Space cooling in emerging economies Read the full research here
About the IKEA Foundation
The IKEA Foundation is a strategic philanthropy that focuses its grant making efforts on tackling the two biggest threats to children’s futures: poverty and climate change. It currently grants more than €200 million per year to help improve family incomes and quality of life while protecting the planet from climate change. Since 2009, the IKEA Foundation has granted more than €1.5 billion to create a better future for children and their families. In 2021 the Board of the IKEA Foundation decided to make an additional €1 billion available over the next five years to accelerate the reduction of Greenhouse Gas emissions.
About Systemiq
Systemiq, the system change company, was founded in 2016 to drive the achievement of the Sustainable Development Goals and the Paris Agreement, by transforming markets and business models in five key systems: nature and food, materials and circularity, energy, urban areas, and sustainable finance. A certified B Corp, Systemiq combines strategic advisory with high-impact, on-the-ground work, and partners with business, finance, policy- makers and civil society to deliver system change. Systemiq’s people are based in Brazil, France, Germany, Indonesia, the Netherlands and the UK. Find out more at www.systemiq.earth
About RMI
RMI is an independent nonprofit founded in 1982 that transforms global energy systems through market-driven solutions to align with a 1.5°C future and to secure a clean, prosperous, zero-carbon future for all. We work in the world’s most critical geographies and engage businesses, policymakers, communities, and NGOs to identify and scale energy system interventions that will cut greenhouse gas emissions by at least 50 percent by 2030. RMI has offices in: Basalt and Boulder, Colo.; New York City; Oakland, Calif.; Washington, D.C.; and Beijing.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005235/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
